Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAbbott Laboratories

Abbott Laboratories

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
115.51 USD 6.11 ( 5.58%)
Last update at 2026-11-04T21:06:00Z
VOLUME
12705905
Market Cap
161117.96M
P/E
25.97

Momentum Score

…

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Labor

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
112.12
Low
116.22
High
52 Week Price Range
92.66
Low
136.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Abbott Laboratories is a diversified healthcare company selling medical devices, diagnostics, nutrition products and diabetes care systems worldwide. Long-term growth may be supported by aging populations, rising chronic disease (notably diabetes), demand for diagnostics and diabetes-monitoring innovations, while recurring consumables and emerging-market expansion could support revenue.
Principal risks are regulatory and reimbursement setbacks, intensifying competition, product recall or approval delays, and currency or geopolitical exposure that could affect international sales.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
109.40
Dividend Yield
2.54%
Revenue TTM
45134.00M
Revenue Per Share
25.92
Gross Profit TTM
25485.00M
Debt / Equity
0.29
ROE
12.96%
Net Debt
6545.00M
ROCE
12.54%
Diluted EPS TTM
3.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 8466.00M 7013.00M 6664.00M 8306.00M 8211.00M
Net income 6524.00M 13402.00M 5723.00M 6933.00M 7071.00M
Selling general administrative 12378.00M 11697.00M 11198.00M 11012.00M 11324.00M
Gross profit 24607.00M 21325.00M 20037.00M 24511.00M 24538.00M
Reconciled depreciation 3116.00M 3218.00M 3237.00M 2013.00M 2047.00M
Ebit 8807.00M 7616.00M 7362.00M 8362.00M 8425.00M
Ebitda 11553.00M 10834.00M 10605.00M 10696.00M 10749.00M
Depreciation and amortization 2746.00M 3218.00M 3243.00M 2334.00M 2324.00M
Non operating income net other - - - 502.00M 319.00M
Operating income 8048.00M 6825.00M 6435.00M 8362.00M 8425.00M
Other operating expenses 36280.00M 35099.00M 33674.00M 35291.00M 34650.00M
Interest expense 341.00M 603.00M 698.00M 375.00M 490.00M
Tax provision 1942.00M -6389.00M 1027.00M 1373.00M 1140.00M
Interest income 135.00M 344.00M 384.00M 377.00M 491.00M
Net interest income -185.00M -215.00M -248.00M -375.00M -490.00M
Extraordinary items - - - - 0.00M
Income tax expense 1942.00M -6389.00M 941.00M 1373.00M 1140.00M
Total revenue 44328.00M 41950.00M 40109.00M 43653.00M 43075.00M
Total operating expenses 16586.00M 14474.00M 13602.00M 16149.00M 16113.00M
Cost of revenue 19721.00M 20625.00M 20072.00M 19142.00M 18537.00M
Total other income expense net 418.00M 188.00M 229.00M -56.00M -214.00M
Net income from continuing ops 6524.00M 13402.00M 5162.00M 6933.00M 7071.00M
Net income applicable to common shares 6524.00M 13402.00M 5723.00M 6933.00M 7071.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 86713.00M 81414.00M 73214.00M 74438.00M 75196.00M
Intangible assets 5526.00M 6647.00M 8815.00M 10454.00M 12739.00M
Other current assets 2640.00M 2570.00M 2256.00M 2663.00M 2346.00M
Total liab 33942.00M 33513.00M 34387.00M 37533.00M 39172.00M
Total stockholder equity 52130.00M 47664.00M 38603.00M 36686.00M 35802.00M
Other current liab 8378.00M 7614.00M 7729.00M 8631.00M 7943.00M
Common stock 25527.00M 25153.00M 24869.00M 24709.00M 24470.00M
Capital stock 25527.00M 25153.00M 24869.00M 24709.00M 24470.00M
Retained earnings 49781.00M 47261.00M 37554.00M 35257.00M 31528.00M
Other liab - - - 6579.00M 7815.00M
Good will 24035.00M 23108.00M 23679.00M 22799.00M 23231.00M
Other assets 17296.00M 15384.00M 5975.00M 4917.00M 4059.00M
Cash 8522.00M 7616.00M 6896.00M 9882.00M 9799.00M
Cash and equivalents 8522.00M 7616.00M 6896.00M 9882.00M 9799.00M
Total current liabilities 16496.00M 14157.00M 13841.00M 15489.00M 13105.00M
Current deferred revenue - - 174.00M - -
Net debt 6545.00M 7659.00M 8977.00M 7834.00M 9207.00M
Short term debt 3309.00M 1754.00M 1325.00M 2251.00M 754.00M
Short long term debt 3033.00M 1500.00M 1080.00M 2251.00M 754.00M
Short long term debt total 15067.00M 15275.00M 15873.00M 17716.00M 19006.00M
Other stockholder equity -17177.00M -16844.00M -15981.00M -15229.00M -11822.00M
Property plant equipment 12942.00M 11733.00M 11276.00M 9162.00M 8959.00M
Total current assets 25996.00M 23656.00M 22670.00M 25224.00M 24239.00M
Long term investments 918.00M 886.00M 799.00M 766.00M 816.00M
Net tangible assets - - - 10955.00M -2189.00M
Short term investments 417.00M 351.00M 383.00M 288.00M 450.00M
Net receivables 7929.00M 6925.00M 6565.00M 8881.00M 6487.00M
Long term debt 9896.00M 12625.00M 13599.00M 14522.00M 17296.00M
Inventory 6488.00M 6194.00M 6570.00M 6173.00M 5157.00M
Accounts payable 4240.00M 4195.00M 4295.00M 4607.00M 4408.00M
Noncontrolling interest in consolidated entity - - - 219.00M 222.00M
Accumulated other comprehensive income -6001.00M -7906.00M -7839.00M -8051.00M -8374.00M
Common stock total equity - - - 24709.00M 24470.00M
Retained earnings total equity - - - 35257.00M 31528.00M
Treasury stock - - - - -11822.00M
Non currrent assets other 17296.00M 15384.00M 5975.00M - -
Non current assets total 60717.00M 57758.00M 50544.00M 49214.00M 50957.00M
Capital lease obligations 931.00M 896.00M 949.00M 943.00M 956.00M
Long term debt total 9896.00M 12625.00M 13599.00M 14522.00M 17296.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -164.00M -2338.00M -2941.00M -33.00M -96.00M
Change to liabilities - - - 37.00M 380.00M
Total cashflows from investing activities -2422.00M -2338.00M -3133.00M -1740.00M -2008.00M
Net borrowings -1614.00M -537.00M -2475.00M 47.00M -248.00M
Total cash from financing activities -6309.00M -5404.00M -7091.00M -7636.00M -5494.00M
Change to operating activities - - - -75.00M -312.00M
Net income 6524.00M 13402.00M 5723.00M 6933.00M 7071.00M
Change in cash 906.00M 720.00M -2986.00M 83.00M 2961.00M
Begin period cash flow 7616.00M 6896.00M 9882.00M 9799.00M 6838.00M
End period cash flow 8522.00M 7616.00M 6896.00M 9882.00M 9799.00M
Total cash from operating activities 9566.00M 8558.00M 7261.00M 9581.00M 10533.00M
Depreciation 3116.00M 3218.00M 3243.00M 3267.00M 3538.00M
Other cashflows from investing activities 18.00M 9.00M 22.00M 70.00M -27.00M
Dividends paid 4116.00M 3836.00M 3556.00M -3309.00M -3202.00M
Change to inventory 195.00M -58.00M -232.00M -1413.00M -456.00M
Change to account receivables -652.00M -691.00M -356.00M -68.00M -383.00M
Sale purchase of stock -893.00M -1295.00M -1227.00M -3795.00M -2299.00M
Other cashflows from financing activities -82.00M 264.00M 167.00M 221.00M 55.00M
Change to netincome - - - 685.00M 640.00M
Capital expenditures 2171.00M 2207.00M 2202.00M 1777.00M 1885.00M
Change receivables - - - -68.00M -383.00M
Cash flows other operating - - - 140.00M -257.00M
Cash and cash equivalents changes - - - 205.00M 3031.00M
Change in working capital -803.00M -9217.00M -2475.00M -1519.00M -771.00M
Stock based compensation 664.00M 673.00M 644.00M 685.00M 640.00M
Other non cash items 65.00M 482.00M 126.00M 215.00M 55.00M
Free cash flow 7395.00M 6351.00M 5059.00M 7804.00M 8648.00M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABT
Abbott Laboratories		 6.11
5.58%		 115.51 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 6.08
6.15%		 104.96 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 29.10
9.37%		 339.65 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 48.37 39.57 21.32 3.01 3.29 2.95 16.92
SMMNY
Siemens Healthineers AG ADR		 1.20
4.98%		 25.32 39.49 21.10 3.01 3.25 2.95 16.92

Profile*

Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Labor

100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400

224 667 6100

https://www.abbott.com

122000

Name Title Year Born
Mr. Robert B. Ford Chairman, Pres & CEO 1974
Mr. Robert E. Funck Jr. Exec. VP of Fin. & CFO 1961
Mr. Hubert L. Allen Exec. VP, Gen. Counsel & Sec. 1966
Mr. Daniel Gesua Sive Salvadori Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products 1979
Ms. Andrea F. Wainer Exec. VP of Rapid & Molecular Diagnostics 1970
Mr. Scott Michael Leinenweber VP of Investor Relations, Licensing & Acquisitions 1972
James E. Young VP and Chief Ethics & Compliance Officer NA
Ms. Melissa Brotz VP of Public Affairs & Corp. Marketing NA
Ms. Elaine R. Leavenworth Sr. VP and Chief Marketing & External Affairs Officer 1959
Ms. Mary K. Moreland Exec. VP of HR 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…